Plasma Derived Therapy Trends and Forecast
The future of the global plasma derived therapy market looks promising with opportunities in the hemophilia, primary immunodeficiency disease, and idiopathic thrombocytopenic purpura markets. The global plasma derived therapy market is expected to grow with a CAGR of 7.2% from 2024 to 2030. The major drivers for this market are rising rates of unusual and chronic diseases within the population, growing demand in developing countries for medications made from plasma, along with the rapid research and development programs by the government.
• Lucintel forecasts that, within the product category, immunoglobulin is expected to witness the highest growth over the forecast period due to rise in use of immunoglobulins for the treatment of several complex diseases.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to significant initiatives to support the therapeutic system from the government and corporate sector, and the number of plasma collecting units in this business has expanded dramatically in recent years, leading to a substantial increase in market size.
A more than 150-page report is developed to help in your business decisions.
Emerging Trends in the Plasma Derived Therapy Market
Emerging trends in the plasma-derived therapy market shaping its future applications and market dynamics:
• Personalized Treatments: There is a growing trend towards personalized plasma-derived therapies tailored to individual patient needs. This trend aims to enhance treatment efficacy and minimize side effects by customizing therapies based on genetic and clinical profiles.
• Technological Advancements: Advances in biotechnology and plasma processing technologies are improving the quality and efficacy of plasma-derived therapies. Innovations such as recombinant DNA technology and improved purification methods are driving this trend.
• Expansion into Emerging Markets: The plasma-derived therapy market is expanding into emerging markets, driven by increasing healthcare infrastructure and rising demand for advanced treatments. Countries like China and India are key regions for market growth.
• Increased Investment in R&D: There is a heightened focus on research and development to discover new therapies and improve existing ones. Investment in R&D is crucial for developing novel treatments for rare and complex diseases.
• Regulatory Changes: Evolving regulatory frameworks are influencing the plasma-derived therapy market. Changes in regulations are aimed at enhancing safety and efficacy standards, which impact product development and market access.
• Collaborations and Partnerships: Companies are forming strategic collaborations and partnerships to advance plasma-derived therapy development. These alliances help share resources, expertise, and accelerate the development of new treatments.
• Patient-Centric Approaches: There is a shift towards patient-centric approaches in plasma-derived therapy, focusing on improving patient outcomes and experiences. This includes better support services and patient education.
Emerging trends in the plasma-derived therapy market include personalized treatments, technological advancements, and expansion into emerging markets. Increased investment in R&D, regulatory changes, collaborations, and patient-centric approaches are shaping the marketÄX%$%Xs future.
Recent Developments in the Plasma Derived Therapy Market
Ongoing innovations and advancements in various sectors of the plasma-derived therapy market are highlighted by recent developments:
• FDA Approvals: Recent FDA approvals for new plasma-derived therapies are expanding treatment options for patients with immune deficiencies and bleeding disorders. These approvals are driving market growth and increasing the availability of advanced therapies.
• Technological Innovations: The development of new technologies in plasma processing and purification is improving the efficiency and safety of plasma-derived therapies. Innovations are enhancing the quality of treatments and expanding their applications.
• Global Expansion: Companies are expanding their operations globally, with new plasma collection centers and production facilities being established in emerging markets. This expansion aims to meet the growing demand for plasma-derived therapies worldwide.
• Increased Collaboration: There is a rise in collaborations between pharmaceutical companies and research institutions to advance plasma-derived therapies. These partnerships are focused on developing new treatments and improving existing ones.
• Regulatory Developments: Changes in regulatory policies are impacting the plasma-derived therapy market. New guidelines are being introduced to enhance product safety and efficacy, influencing the development and approval processes.
Recent developments in the plasma-derived therapy market include FDA approvals, technological innovations, global expansion, increased collaboration, and regulatory changes. These factors are driving market growth and enhancing the availability of advanced therapies.
Strategic Growth Opportunities for Plasma Derived Therapy Market
The plasma-derived therapy market offers numerous strategic growth opportunities, particularly in key applications, which are essential for various industries.
• Emerging Markets Expansion: Expanding into emerging markets presents significant growth opportunities due to rising healthcare needs and increasing investment in healthcare infrastructure. Targeting regions with growing demand for advanced therapies can drive market expansion.
• R&D Investments: Investing in research and development to discover new plasma-derived therapies and improve existing ones offers substantial growth potential. Innovations in therapy development can lead to the introduction of novel treatments and applications.
• Technological Advancements: Leveraging technological advancements in plasma processing and purification can enhance the efficiency and safety of plasma-derived therapies. Incorporating cutting-edge technologies can provide a competitive edge and open new market opportunities.
• Strategic Partnerships: Forming strategic partnerships with other pharmaceutical companies, research institutions, and healthcare providers can facilitate market growth. Collaborations can help accelerate therapy development and expand market reach.
• Regulatory Strategy: Adapting to changing regulatory environments and engaging in proactive regulatory strategies can enhance market access and streamline the approval process for new therapies. Staying ahead of regulatory trends is crucial for successful market entry.
Strategic growth opportunities in the plasma-derived therapy market include expanding into emerging markets, investing in R&D, leveraging technological advancements, forming strategic partnerships, and adapting to regulatory changes. These opportunities can drive market growth and enhance competitive positioning.
Plasma Derived Therapy Market Driver and Challenges
The plasma-derived therapy market is influenced by several drivers and challenges that shape its growth and development in the industry.
The factors responsible for driving the plasma-derived therapy market include:
• Increasing prevalence of blood disorders: The rising prevalence of blood disorders, such as hemophilia and immune deficiencies, is driving demand for plasma-derived therapies. This growing patient population necessitates advanced treatments.
• Technological innovations: Advances in plasma processing and purification technologies are improving the quality and efficiency of plasma-derived therapies. Innovations are making treatments more effective and accessible.
• Government support: Government initiatives and funding for research and development in plasma-derived therapies support market growth. Policies aimed at improving healthcare access and supporting new therapies drive market expansion.
• Rising healthcare expenditure: Increased healthcare expenditure, particularly in developed and emerging markets, supports the growth of the plasma-derived therapy market. Higher investments in healthcare infrastructure and treatment options contribute to market growth.
• Growing awareness: Increased awareness of plasma-derived therapies and their benefits is driving demand. Education and outreach efforts are enhancing understanding and acceptance of these advanced treatments.
Challenges in the plasma-derived therapy market include:
• High costs: The high cost of plasma-derived therapies can be a barrier to access for some patients and healthcare systems. Addressing cost challenges and improving affordability is essential for market growth.
• Regulatory hurdles: Navigating complex regulatory requirements can be challenging and time-consuming. Ensuring compliance with evolving regulations is crucial for successful product development and market entry.
• Supply chain issues: Ensuring a consistent and reliable supply of plasma for therapy production can be challenging. Addressing supply chain issues and improving plasma collection and processing is vital for market stability.
• Competitive market: The plasma-derived therapy market is highly competitive, with numerous companies developing and offering similar products. Differentiating products and demonstrating unique value propositions are critical for market success.
• Technological limitations: While advancements are being made, there are still technological limitations in plasma processing and therapy development. Overcoming these limitations is essential for improving treatment efficacy and expanding applications.
The plasma-derived therapy market is driven by increasing prevalence of blood disorders, technological innovations, government support, rising healthcare expenditure, and growing awareness. However, challenges such as high costs, regulatory hurdles, supply chain issues, market competition, and technological limitations need to be addressed to ensure market growth and accessibility.
List of Plasma Derived Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies plasma derived therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the plasma derived therapy companies profiled in this report include-
• CSL Behring
• Takeda Pharmaceutical
• BPL
• ADMA Biologics
• Biotest
• Octapharma
• Grifols
• Kamada Pharmaceuticals
• SK Plasma
• Pfizer
Plasma Derived Therapy by Segment
The study includes a forecast for the global plasma derived therapy by product, application, and region.
Plasma Derived Therapy Market by Product [Analysis by Value from 2018 to 2030]:
• Immunoglobulin
• Coagulation Factor
• Albumin
• Others
Plasma Derived Therapy Market by Application [Analysis by Value from 2018 to 2030]:
• Hemophilia
• Primary Immunodeficiency Disease
• Idiopathic Thrombocytopenic Purpura
• Others
Plasma Derived Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Plasma Derived Therapy Market
Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are the recent developments in plasma-derived therapy in key regions:
• United States: The U.S. has seen substantial growth in the plasma-derived therapy market, with advancements in therapies for immune deficiencies and bleeding disorders. Increased investment in research and development, coupled with FDA approvals for new therapies, is driving market expansion.
• Germany: Germany is a leader in Europe for plasma-derived therapies, focusing on enhancing the safety and efficacy of these treatments. Recent developments include new production facilities and collaborations aimed at improving plasma collection and processing technologies.
• China: China is rapidly advancing its plasma-derived therapy market through significant investments in domestic plasma collection centers and production facilities. The country is also expanding its range of therapies to include treatments for rare and complex diseases.
• Japan: Japan is making strides in the plasma-derived therapy market by focusing on innovative therapies and improving patient access. Recent developments include partnerships with international companies to enhance research and development capabilities.
• India: India is witnessing growth in the plasma-derived therapy market, driven by increased healthcare investment and the establishment of new plasma collection centers. The focus is on expanding the availability of therapies for various blood disorders and immune system deficiencies.
Features of the Global Plasma Derived Therapy Market
Market Size Estimates: Plasma derived therapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Plasma derived therapy market size by product, application, and region in terms of value ($B).
Regional Analysis: Plasma derived therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product, application, and regions for the plasma derived therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the plasma derived therapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What is the growth forecast for plasma derived therapy market?
Answer: The global plasma derived therapy market is expected to grow with a CAGR of 7.2% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the plasma derived therapy market?
Answer: The major drivers for this market are rising rates of unusual and chronic diseases within the population, growing demand in developing countries for medications made from plasma, along with the rapid research and development programs by the government.
Q3. What are the major segments for plasma derived therapy market?
Answer: The future of the global plasma derived therapy market looks promising with opportunities in the hemophilia, primary immunodeficiency disease, and idiopathic thrombocytopenic purpura markets.
Q4. Who are the key plasma derived therapy market companies?
Answer: Some of the key plasma derived therapy companies are as follows:
• CSL Behring
• Takeda Pharmaceutical
• BPL
• ADMA Biologics
• Biotest
• Octapharma
• Grifols
• Kamada Pharmaceuticals
• SK Plasma
• Pfizer
Q5. Which plasma derived therapy market segment will be the largest in future?
Answer: Lucintel forecasts that immunoglobulin is expected to witness the highest growth over the forecast period due to rise in use of immunoglobulins for the treatment of several complex diseases.
Q6. In plasma derived therapy market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness the highest growth over the forecast period due to significant initiatives to support the therapeutic system from the government and corporate sector, and the number of plasma collecting units in this business has expanded dramatically in recent years, leading to a substantial increase in market size.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the plasma derived therapy market by product (immunoglobulin, coagulation factor, albumin, and others), application (hemophilia, primary immunodeficiency disease, idiopathic thrombocytopenic purpura, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Plasma Derived Therapy Market, Plasma Derived Therapy Market Size, Plasma Derived Therapy Market Growth, Plasma Derived Therapy Market Analysis, Plasma Derived Therapy Market Report, Plasma Derived Therapy Market Share, Plasma Derived Therapy Market Trends, Plasma Derived Therapy Market Forecast, Plasma Derived Therapy Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.